Better Therapeutics Accounts Payable

As of the most recent data (September 2023), MCAD shows a accounts payable of $2.3M. That compares with $1.3M in the prior-year period — up 83.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MCAD's accounts payable is now $2.3M (was $1.3M) — a 83.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Better Therapeutics is outperforming or lagging.

Tracking MCAD's accounts payable over time shows whether Better Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $2.3M That compares with $1.3M in the prior-year period — up 83.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Better Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $2.3M) with ownership activity and broader fundamentals.